Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Leukemia

Volumn 27, Issue 4, 2013, Pages 780-791

  Fernandez De Larrea C ^a   Kyle, R A ^b   Durie, B G M ^c   Ludwig, H ^d   Usmani, S ^e   Vesole, D H ^f   Hajek, R ^g   San Miguel, J F ^h   Sezer, O ⁱ   Sonneveld, P ^j   Kumar, S K ^b   Mahindra, A ^k   Comenzo, R ^l   Palumbo, A ^m   Mazumber, A ⁿ   Anderson, K C ^o   Richardson, P G ^o   Badros, A Z ^p   Caers, J ^q   Cavo, M ^r   Leleu, X ^s   Dimopoulos, M A ^t   Chim, C S ^u   Schots, R ^v   Noeul, A ^w   Fantl, D ^x   Mellqvist, U H ^y   Landgren, O ^z   Chanan Khan, A ^aa   Moreau, P ^ab   Fonseca, R ^ac   Merlini, G ^ad   Lahuerta, J J ^ae   Blade J ^a   Orlowski, R Z ^af   Shah, J J ^af   more..

^a HOSPITAL CLÍNIC   (Spain)

^b MAYO CLINIC   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d WILHELMINEN HOSPITAL   (Austria)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^h Centro de Investigacion del Cancer   (Spain)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^l TUFTS MEDICAL CENTER   (United States)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ NEW YORK UNIVERSITY   (United States)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p UNIVERSITY OF MARYLAND   (United States)

^q UNIVERSITY OF LIÈGE   (Belgium)

^r UNIVERSITY OF BOLOGNA   (Italy)

^s LILLE UNIVERSITY HOSPITAL   (France)

^t UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^u QUEEN MARY HOSPITAL   (Hong Kong)

^v Division of Clinical Haematology Ziekenhuis University   (Belgium)

^w Hosp Univ Ruiz y Páez   (Venezuela)

^x HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^y SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^z NATIONAL CANCER INSTITUTE   (United States)

^aa MAYO CLINIC   (United States)

^ab NANTES UNIVERSITY HOSPITAL   (France)

^ac MAYO CLINIC   (United States)

^ad UNIVERSITY OF PAVIA   (Italy)

^ae HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^af UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

bortezomib; cytogenetics; myeloma; plasma cell leukemia; prognosis; transplantation

Indexed keywords

BETA1 INTEGRIN; BORTEZOMIB; CARMUSTINE; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; GELATINASE B; GLUCOCORTICOID; INTERLEUKIN 3; INTERLEUKIN 6 RECEPTOR; MELPHALAN; PREDNISONE; PROTEIN P16; VASCULAR CELL ADHESION MOLECULE 1; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CELL COUNT; CONSENSUS; DISEASE COURSE; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE SEQUENCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; LONG TERM SURVIVAL; MAINTENANCE THERAPY; OVERALL SURVIVAL; PLASMA CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED;

EID: 84876141059     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.336     Document Type: Review

References (92)

1. Gluzinski A, Reichentein M. Myeloma und leucaemia lymphatica plasmocellularis. Wien Klin Wochenschr 1906; 19: 336.
2. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med 1974; 133: 813-818.
3. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987; 83: 1062-1068.
4. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. Br J Haematol 1994; 88: 754-759.
5. García-Sanz R, Orfao A, González M, Tabernero MD, Bladé J, Moro MJ et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93: 1032-1037.
6. Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004. Cancer 2009; 115: 5734-5739.
7. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22: 1044-1052.
8. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haemat 2003; 121: 749-757.
9. Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13: 1259-1272.
10. Costello R, Sainty D, Bouabdallah R, Fermand JP, Delmer A, Diviné M et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res 2001; 25: 103-107.
11. Colović M, Janković G, Suvajdzić N, Milić N, Dordević V, Janković S. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol 2008; 25: 154-160.
12. Peijing Q, Yan X, Yafei W, Dehui Z, Zengjun L, Junyuan Q et al. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China. Acta Haematol 2009; 121: 47-51.
13. Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 2011; 22: 1628-1635.
14. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50: 29-40.
15. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19: 379-390.
16. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991; 115: 931-935.
17. Butterworth Jr CE, Frommeyer Jr W, Riser WH. Erythrophagocytosis in a case of plasma cell leukemia. Blood 1953; 8: 519-523.
18. Minauchi K, Fujie T, Matsubara N, Kasahara H, Ogura Y, Tamura M et al. Primary plasma cell leukemia (IgD-lambda) with hyperammonemia. Nihon Naika Gakkai Zasshi 2004; 93: 139-141.
19. Fernández de Larrea C, Cibeira MT, Vallansot R, Colomo L, Bladé J. Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature. Clin Lymphoma Myeloma 2008; 8: 312-314.
20. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005; 23: 5668-5674.
21. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106: 2276-2279.
22. Shtalrid M, Shvidel L, Vorst E. Polyclonal reactive peripheral blood plasmacytosis mimicking plasma cell leukemia in a patient with Staphylococcal sepsis. Leuk Lymphoma 2003; 44: 379-380.
23. Touzeau C, Pellat-Deceunynck C, Gastinne T, Accard F, Jego G, Avet-Loiseau H et al. Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications. Leuk Lymphoma 2007; 48: 207-208.
24. Toma VA, Retief FP, Potgieter GM, Anderson JD. Plasma cell leukaemia. Diagnostic problems in our experience with 11 cases. Acta Haematol 1980; 63: 136-145.
25. Woodruff RK, Malpas JS, Paxton AM, Lister TA. Plasma cell leukemia (PCL): A report on 15 patients. Blood 1978; 52: 839-845.
26. Kosmo MA, Gale RP. Plasma cell leukemia. Semin Hematol 1987; 24: 202-208.
27. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117: 4701-4705.
28. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011; 117: 4696-4700.
29. Pellat-Deceunynck C, Barillé S, Jego G, Puthier D, Robillard N, Pineau D et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998; 12: 1977-1982.
30. Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol 2003; 121: 36-43.
31. Guikema JE, Vellenga E, Abdulahad WH, Hovenga S, Bos NA. CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases. Br J Haematol 2004; 124: 299-308.
32. Walters M, Olteanu H, Van Tuinen P, Kroft SH. CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic sub-group. Br J Haematol 2010; 149: 292-293.
33. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG et al. The role of bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007; 21: 1007-1034.
34. Luque R, García-Trujillo JA, Cámara C, Moreno A, Eiras P, Roy G et al. CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression. Br J Haematol 2002; 119: 70-78.
35. Pérez-André s M, Almeida J, Martín-Ayuso M, Moro MJ, Martín-Nuñez G, Galende J et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005; 19: 449-455.
36. Kraj M, Kopeć-Szlezak J, Pog"ód R, Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res 2011; 35: 169-176.
37. Vande Broek I, Vanderkerken K, Van Camp B, Van Riet. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis 2008; 25: 325-334.
38. Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 2006; 91: 200-206.
39. Oliveira AM, Maria DA, Metzger M, Linardi C, Giorgi RR, Moura F et al. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 2009; 33: 970-973.
40. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351.
41. Zhang XG, Bataille R, Widjenes J, Klein B. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 1992; 69: 1373-1376.
42. Bladé J, López-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol 1991; 79: 523-525.
43. Kobayashi M, Tanaka J, Imamura M, Maeda S, Iwasaki H, Tanaka M et al. Upregulation of IL-6-receptors by IL-3 on a plasma cell leukaemia cell line which proliferates dependently on both IL-3 and IL-6. Br J Haematol 1993; 83: 535-538.
44. Heuberger L, Costello RT, Petit N, Fripiat F, Gastaut JA. First case of plasma-cell leukaemia co-existing with human immunodeficiency virus infection. Leukemia 1998; 12: 103-104.
45. Duprez R, Lacoste V, Hermouet S, Troussard X, Valensi F, Merle-Beral H et al. Plasma-cell leukemia and human herpesvirus 8 infection. Leukemia 2004; 18: 1903-1904.
46. Hermouet S, Corre I, Gassin M, Bigot-Corbel E, Sutton CA, Casey JW. Hepatitis C virus, human herpesvirus 8, and the development of plasma-cell leukemia. N Engl J Med 2003; 348: 178-179.
47. Azar GM, Gogineni SK, Hyde P, Verma RS. Highly complex chromosomal abnormalities in plasma cell leukemia as detected by FISH technique. Leukemia 1997; 11: 772-774.
48. Taniwaki M, Nishida K, Ueda Y, Takashima T. Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Leuk Lymphoma 1996; 21: 25-30.
49. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99: 3735-3741.
50. Fonseca R, Hoyer JD, Aguayo P, Jalal SM, Ahmann GJ, Rajkumar SV et al. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk Lymphoma 1999; 35: 599-605.
51. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terré C, Lafage-Pochitaloff M et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique. Blood 2001; 97: 822-825.
52. Chiecchio L, Dagrada GP, White HE, Towsend MR, Protheroe RK, Cheung KL et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 2009; 48: 624-636.
53. Chang H, Yeung J, Xu W, Ning Y, Patterson B. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. Br J Haematol 2006; 134: 613-615.
54. Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009; 33: 259-262.
55. Gutiérrez NC, Hernández JM, García JL, Cañizo MC, González M, Hernández J et al. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia 2001; 15: 840-845.
56. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R. Rearrangements of the c-myc oncogene are present in 15 of primary human multiple myeloma tumors. Blood 2001; 98: 3082-3086.
57. Sümegi J, Hedberg T, Björkholm M. Amplification of the c-myc oncogene in human plasma-cell leukemia. Int J Cancer 1985; 36: 367-371.
58. Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001; 18: 212-224.
59. Urashima M, Teoh G, Ogata A, Chauhan D, Treon SP, Sugimoto Y et al. Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. Clin Cancer Res 1997; 3: 2173-2179.
60. Mateos MV, Garcia-Sanz R, López-Pé rez R, Balanzategui A, Gonzá lez MI, Fernández-Calvo J et al. p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J 2001; 2: 146-149.
61. Bollati V, Fabris S, Pegoraro V, Ronchetti D, Mosca L, Deliliers GL et al. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis 2009; 30: 1330-1335.
62. Walker BA, Wardell CP, Boyd KD, Smith EM, Nyegaard M, Petrucci MT et al. Hypermethylation is a key feature of the transition of multiple myeloma to plasma cell leukemia. Blood (ASH Annual Meeting Abstract) 2010; 116 Abstract 535.
63. Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with total therapy protocols. Leukemia 2012; 26: 2398-2405.
64. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Whole genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution and clonal tides. Blood 2012; 120: 1060-1066.
65. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012; 26: 1091-1097.
66. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
67. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
68. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
69. Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78: 288-294.
70. Johnston RE, Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 2002; 43: 351-354.
71. Bauduer F. Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma. Br J Haematol 2002; 117: 996-997.
72. Petrucci MT, Martini V, Levi A, Gallucci C, Palumbo G, Del Bianco P et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma 2007; 48: 180-182.
73. Ballanti S, Mastrodicasa E, Bolli N, Lotti F, Capolsini I, Berchicci L et al. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nat Clin Pract Oncol 2007; 4: 722-725.
74. Pretz J, Medeiros BC. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: no recurrence with subsequent lenalidomide therapy. Am J Hematol 2009; 84: 698-699.
75. Benson Jr DM, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma 2007; 48: 1423-1425.
76. Musto P, Pietrantuono G, Guariglia R, Villani O, Martorelli MC, D'Auria F et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008; 32: 1637-1638.
77. Olivieri A, Attolico I, Cimminiello M, Discepoli G, Cifarelli RA. Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report. Leuk Res 2009; 33: e191-e193.
78. Guglielmelli T, Merlini R, Giugliano E, Saglio G. Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol 2009; 2009: 867380.
79. Musto P, D'Auria F, Petrucci MT, Levi A, Cascavilla N, Falcone A et al. Final results of a phase ii study evaluating lenalidomide in combination with low dose dexamethasone as first line therapy for primary plasma cell leukemia. Blood (ASH Annual Meeting Abstracts) 2011; 118 Abstract 2925.
80. Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114: 665-667.
81. van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood 2012; 120: 2376-2389.
82. Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109: 2285-2290.
83. D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 2012; 23: 1499-1502.
84. Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D et al. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk 2011; 11: 507-511.
85. Libby E, Candelaria-Quintana D, Moualla H, Abdul-Jaleel M, Rabinowitz I. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol 2010; 85: 733-734.
86. Al-Nawakil C, Tamburini J, Bardet V, Chapuis N, Bourry E, Roux C et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma 2008; 49: 2012-2014.
87. Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res 2008; 32: 1153-1156.
88. Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010; 95: 804-809.
89. Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120: 1589-1596.
90. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-1791.
91. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
92. Morris C, Iacobelli S, Gahrton G, Garderet Laurent, Drake Mary, Anja van Biezen et al. Has allogeneic transplantation a role in the management of plasma cell leukaemia? A study on behalf of the myeloma subcomittee of the Chronic Leukaemia Working Party of the EBMT. Blood (ASH Annual Meeting Abstracts) 2011; 118 Abstract 2008.